Correction: The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals

TY - JOUR

T1 - Correction

T2 - The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals

AU - Henderson, C J

AU - McLaren, A W

AU - MacLeod, A K

AU - Lin, D

AU - Cameron, A R

AU - Chatham, L R

AU - Moggs, J

AU - Inesta-Vaquera, F

AU - Thomson, John P

AU - Meehan, Richard R

AU - Chakravarty, P

AU - Schwarz, M

AU - Roland Wolf, C

N1 - Publisher Copyright: © Crown 2026.

PY - 2026/6/27

Y1 - 2026/6/27

N2 - In Figure 1B of this article, the bottom left panel (hCAR/hPXR + PB) was previously published in McMahon et al. (2019) Molecular Pharmacology paper (https://doi.org/10.1124/mol.118.113555) Figure 3A (bottom left panel, hCAR/hPXR + PB)), by the same lab. The image was reused here for illustrative purposes to demonstrate LacZ expression in the CYP2B-LacZ reporter mouse model following phenobarbital treatment. Although the use of this model was described in the Materials and Methods section, referencing McMahon et al. (2019), the prior publication of this specific image was not explicitly acknowledged, and for this we apologise. This clarification does not affect the results or conclusions of the article. A: … B: Transgenic mice carrying a CYP2B6-LacZ reporter and either wild-type (mCar/mPxr) or humanised for CAR and PXR (hCAR/hPXR) were treated with CITCO (10 mg/kg, ip, daily for 4d) or phenobarbital (PB; 80 mg/kg, ip daily, 3d), and sacrificed the following day.

AB - In Figure 1B of this article, the bottom left panel (hCAR/hPXR + PB) was previously published in McMahon et al. (2019) Molecular Pharmacology paper (https://doi.org/10.1124/mol.118.113555) Figure 3A (bottom left panel, hCAR/hPXR + PB)), by the same lab. The image was reused here for illustrative purposes to demonstrate LacZ expression in the CYP2B-LacZ reporter mouse model following phenobarbital treatment. Although the use of this model was described in the Materials and Methods section, referencing McMahon et al. (2019), the prior publication of this specific image was not explicitly acknowledged, and for this we apologise. This clarification does not affect the results or conclusions of the article. A: … B: Transgenic mice carrying a CYP2B6-LacZ reporter and either wild-type (mCar/mPxr) or humanised for CAR and PXR (hCAR/hPXR) were treated with CITCO (10 mg/kg, ip, daily for 4d) or phenobarbital (PB; 80 mg/kg, ip daily, 3d), and sacrificed the following day.

UR - https://www.scopus.com/pages/publications/105043339069

U2 - 10.1007/s00204-026-04463-3

DO - 10.1007/s00204-026-04463-3

M3 - Article

C2 - 42362751

SN - 0340-5761

JO - Archives of Toxicology

JF - Archives of Toxicology

ER -